Amneal Pharmaceuticals, Inc.
AMRX
$6.98
$0.010.14%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.40% | 13.29% | 17.15% | 18.23% | 1.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.40% | 13.29% | 17.15% | 18.23% | 1.18% |
| Cost of Revenue | 19.69% | 11.97% | 19.23% | 14.09% | 0.28% |
| Gross Profit | 16.17% | 15.52% | 13.55% | 26.41% | 2.79% |
| SG&A Expenses | 18.06% | 5.03% | 10.32% | 10.28% | 6.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 100.00% |
| Total Operating Expenses | 19.20% | 13.23% | 15.70% | 12.65% | 2.55% |
| Operating Income | 12.21% | 13.75% | 27.13% | 77.54% | -8.29% |
| Income Before Tax | 81.65% | -32.82% | -31.20% | -701.21% | -990.28% |
| Income Tax Expenses | -45.13% | 276.59% | 15,830.43% | 821.56% | 649.97% |
| Earnings from Continuing Operations | 77.78% | -53.03% | -43.45% | -709.17% | -1,493.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -94.89% | 22.40% | 39.25% | -416.25% | -447.87% |
| Net Income | 68.49% | -101.61% | -49.70% | -1,219.93% | -2,176.69% |
| EBIT | 12.21% | 13.75% | 27.13% | 77.54% | -8.29% |
| EBITDA | 13.98% | 9.20% | 14.32% | 32.58% | -7.61% |
| EPS Basic | 75.22% | -100.80% | -74.97% | -553.95% | -1,315.38% |
| Normalized Basic EPS | -661.54% | -4,600.00% | 104.07% | -75.80% | -91.13% |
| EPS Diluted | 75.22% | -100.83% | -74.97% | -500.00% | -1,210.03% |
| Normalized Diluted EPS | -661.54% | -4,600.00% | 104.10% | -75.80% | -91.13% |
| Average Basic Shares Outstanding | 27.14% | 100.78% | 101.07% | 102.01% | 60.89% |
| Average Diluted Shares Outstanding | 27.14% | 93.90% | 105.93% | 102.01% | 60.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
